Protagenic Therapeutics Reports Fourth Quarter and Full Year

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing

Related Keywords

New York , United States , Massachusetts , Garo Armen , Nasdaq , Advisory Inc , Protagenic Therapeutics Inc , Company Contact , Clinical Stage , Treatment Resistant Depression , Generalized Anxiety Disorder , Protagenic Therapeutics , Clinical Trial , Protocol Progress , Generalized Anxiety , Maurizio Fava , Massachusetts General Hospital , Principal Investigator , Axiom Real Time Metrics , Data Analytics , Full Year , Comprehensive Loss , Access Code , Corticotropin Releasing Factor , Looking Statements , Protagenic Therapeutic , Chief Financial Officer , Relations Contact ,